Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novo Skips August Listing of Ozempic after Pricing Talks Fail
August 23, 2018
- Otsuka Grabs Rights to Osaka Univ. CAR-T Therapy
August 22, 2018
- Daiichi Sankyo Espha Unveils Authorized Generic Pact with AstraZeneca, 3 More Oncology AGs Pending Approval
August 21, 2018
- New Anti-Parkinson’s Drug Obtains POC in PIIa Study: Kyowa Kirin
August 21, 2018
- Japanese OTC Drug Market Grew 1.0% to 828 Billion Yen in 2017: Yano Research
August 21, 2018
- Japan’s 1st Herceptin Biosimilar Now Available, but Use Limited to Gastric Cancer
August 21, 2018
- Mitsubishi Tanabe Going Digital to Shed Drug Discovery and Sales Outlays: President
August 21, 2018
- I/O in Lung Cancer - 2: After MYSTIC Flop, AstraZeneca’s Imfinzi Makes Comeback with Stage III NSCLC Nod
August 20, 2018
- Roche Diagnostics’ EGFR Mutations Test Kit Approved for Determining 1st Line Treatment of Tagrisso
August 20, 2018
- Solasia Licenses PTCL Treatment to Columbia Firm in Latin America
August 20, 2018
- Taiho Files Lonsurf for Gastric Cancer in Japan
August 20, 2018
- FDA Approves Lenvima for 1st-Line Treatment of Liver Cancer
August 17, 2018
- Maviret Top-Seller Drug in Japan in July: Encise Snapshot
August 17, 2018
- Nesp “Biosame” Could Hit Market as Early as December
August 17, 2018
- Japanese Enrollment Begins for PII Venglustat Study for Gaucher’s Disease: Sanofi Genzyme
August 16, 2018
- Daiichi Sankyo Espha Likely to Roll Out Urief, Iressa Authorized Generics: December Listing
August 16, 2018
- FunPep Begins Joint Research with Osaka Univ. to Boost Development of Antibody-Inducing Peptides Using AI
August 16, 2018
- Intuniv Filed for Adult ADHD: Shionogi/Shire
August 16, 2018
- Astellas Snaps Up UK Gene Therapy Firm Quethera
August 10, 2018
- I/O in Lung Cancer - 1: US Merck Sweeping Frontline NSCLC Space with Keytruda
August 10, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…